

WHO

operational
handbook on
tuberculosis

Module 1: Prevention

Tuberculosis preventive treatment



World Health
Organization

WHO operational handbook on tuberculosis

Module 1: Prevention

Tuberculosis preventive treatment

WHO operational handbook on tuberculosis. Module 1: prevention - tuberculosis preventive treatment

ISBN 978-92-4-000290-6 (electronic version)

ISBN 978-92-4-000291-3 (print version)

© World Health Organization 2020

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. WHO operational handbook on tuberculosis. Module 1: prevention - tuberculosis preventive treatment. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Editing and design by Inís Communication

Contents

| | |
|--|------------|
| Acknowledgements..... | iv |
| Abbreviations & acronyms..... | vi |
| Definitions..... | viii |
| Chapter 1. Introduction and approach..... | 2 |
| Chapter 2. Identification of populations for TB preventive treatment..... | 8 |
| Chapter 3. Ruling out TB disease before TB preventive treatment..... | 20 |
| Chapter 4. Testing for TB infection..... | 28 |
| Chapter 5. TB preventive treatment..... | 36 |
| Chapter 6. Safety, management of adverse reactions and other drug-related issues in TB preventive treatment..... | 56 |
| Chapter 7. Adherence to TB preventive treatment..... | 72 |
| Chapter 8. Monitoring and evaluation..... | 82 |
| Chapter 9. Ethics and TB preventive treatment..... | 92 |
| Annexes | |
| Annex 1. List of key messages..... | 95 |
| Annex 2. Coordination mechanisms to support PMTPT..... | 105 |
| Annex 3. Costing considerations for programmatic management of TB preventive treatment..... | 107 |
| Annex 4. Planning checklist for PMTPT..... | 109 |
| Annex 5. Answers to frequently asked questions on TST..... | 111 |
| Annex 6. Answers to frequently asked questions on IGRAs..... | 116 |
| References..... | 119 |

Acknowledgements

This operational handbook was prepared by Avinash Kanchar with inputs from Dennis Falzon and Matteo Zignol under the overall direction of Tereza Kasaeva, Director of the WHO Global TB Programme. The WHO Global TB Programme gratefully acknowledges the contributions of all experts and reviewers involved in the production of the latest update of the WHO guidelines on TB preventive treatment on which this handbook is based, as well as other contributors.

Guideline Development Group of the 2020 guideline revision

The Guideline Development Group (GDG) was composed of Mohammed Al Lawati (Consultant Physician, Oman); Helen Ayles (Infectious Diseases and International Health, London School of Hygiene & Tropical Medicine (LSHTM), Zambia); Rolando Cedillos (Service of Infectious Diseases and Integrated Programme for STI/HIV/AIDS, El Salvador); Padmapriyadarsini Chandrasekaran (National Institute for Research in Tuberculosis, India); Diana Gibb (Medical Research Council, United Kingdom of Great Britain and Northern Ireland); Yohhei Hamada (Research Institute of Tuberculosis (RIT), Japan Anti-Tuberculosis Association (JATA), Japan); Anthony D Harries (International Union Against Tuberculosis and Lung Disease, France; London School of Hygiene and Tropical Medicine, UK); Alexander Kay (Baylor College of Medicine, Global TB Program, Eswatini); Nasehi Mahshid (Department of TB and Leprosy Control, Centre for Control of Communicable Diseases, Ministry of Health and Medical Education, Iran); Alberto Matteelli (University of Brescia, WHO Collaborative Centre for TB/HIV and TB Elimination, Italy); Lindiwe Mvusi (National Department of Health, South Africa); Kuldeep Singh Sachdeva (National Tuberculosis Elimination Programme, India); Nandi Siegfried (Medical Research Council / University of Cape Town, South Africa); Ezio Távora dos Santos Filho (Civil Society Task Force, Brazil); Marieke van der Werf (European Centre for Disease Prevention and Control, Sweden); Wim Vandeveld (Global TB Community Advisory Board, South Africa); and Irina Vasilyeva (Ministry of Health, Russian Federation). The co-chairs of the GDG were Lindiwe Mvusi and Nandi Siegfried. Nandi Siegfried was also the GRADE methodologist.

Observers of the 2020 guideline revision

Sevim Ahmedov (US Agency for International Development (USAID), USA); Draurio Barreira Cravo Neto (UNITAID, Switzerland); Anand Date (Centers for Disease Control and Prevention, USA); Suvanand Sahu (Stop TB Partnership, Switzerland); Surbhi Modi (Centers for Disease Control and Prevention, USA); Harry Hausler (TBHIV Care, South Africa); Lucia Gonzalez Fernandez (International AIDS Society, Switzerland); Anna Scardigli (Global Fund to Fight AIDS, TB and Malaria, Switzerland).

External Review

The External Review Group (ERG) for the 2020 guidelines was composed of Connie Erkens (KNCV TB Foundation, Netherlands); Steve Graham (Center for International Child Health University of Melbourne, Australia); Giovanni B Migliori (Istituti Clinici Scientifici Maugeri, IRCCS and WHO Collaborating Centre for TB and Lung Diseases, Italy); Rohit Sarin (National Institute of TB and Respiratory Diseases, India); James Seddon (Imperial College, UK); Alena Skrahina (Republican Scientific and Practical Centre for Pulmonology and TB, Belarus); and Carrie Tudor (International Council of Nurses, South Africa).

Other persons who responded to a call for public review of the draft handbook in February 2020 are also acknowledged: Grania Brigden; Judith Bruchfeld; Michael Campbell; Martina Casenghi; Joseph Cavanaugh; Rebekah Chang; Gavin Churchyard; Bill Coggin; Jennifer Cohn; Vivian Cox; Jacob Creswell;

Tran Cuc Hong; Kelly Dooley; Rena Fukunaga; Jennifer Furin; Laura Gillini; Martina Hajduk; Agnès Hamzaoui; Jeremy Hill; David Holtzman; Brian Kaiser; Ian Kracalik; Susan Maloney; Carole Mitnick; Lucy Mupfumi; Sreenivas Nair; Nhung Nguyen Viet; Enos Okumu Masini; Regina Osih; Ishani Pathmanathan; Morten Ruhwald; Nabity Scott; Sarita Shah; Alka Singh; Al Story; Marina Tadolini; Oleksandr Telnov; Kassim T Sidibe; Karin Turner and Ed Zuroweste.

Evidence reviewers

The following persons also contributed to the reviews and summarization of evidence for the 2020 guidelines: Mayara Bastos, Jonathon Campbell and Richard (Dick) Menzies (McGill University, Canada); Richard Chaisson, Amita Gupta, Ritesh Ramchandani and Nicole Salazar-Austin (Johns Hopkins University, USA); Susan Swindells (University of Nebraska, USA); Yohhei Hamada (RIT/JATA, Japan); Lynne M. Mofenson (Consultant, WHO HIV Department).

Other WHO staff

WHO is grateful for the contributions of the following WHO headquarters, regional and country office staff: Annabel Baddeley; Deepak Balasubramanian; Vineet Bhatia; Annemieke Brands; Carmen Figueroa; Medea Gegia; Christopher Gilpin; Philippe Glaziou; A.b.m. Tauhidul Islam; David Lowrance; Cecily Miller; Lorenzo Moja; Wilfred Nkhoma; Rafael Lopez Olarte; Malik Parmar; Kalpeshsinh Rahevar; Ranjani Ramachandran; Andreas Reis; Françoise Renaud; Elizaveta Safronova; Kafui Senya; Mukta Sharma; Satvinder Singh; Lana Syed; Hazim Timimi; Martin Van Den Boom; Sabine Verkuil; Wilson Were; Rajendra Prasad Yadav; Askar Yedilbayev.

In addition, WHO acknowledges support from Unitaid-funded projects: IMPAACT4TB – Increasing Market and Public health outcomes through scaling up Affordable Access models of short Course preventive therapy for TB (for permitting content on TPT, 3HP and adherence, also available on <https://www.impaact4tb.org/3hp-documents/>) as well as Catalyzing Pediatric Tuberculosis Innovation (CaP-TB).

The design and layout of this operational handbook was made possible by funding provided by Unitaid.

Abbreviations & acronyms

| | |
|---------------|---|
| 1HP | one month of daily rifapentine plus isoniazid |
| 3HP | three months of weekly rifapentine plus isoniazid |
| 3HR | three months of daily rifampicin plus isoniazid |
| 3TC | lamivudine |
| 4R | four months of daily rifampicin monotherapy |
| 6H | six months of daily isoniazid monotherapy |
| 9H | nine months of daily isoniazid monotherapy |
| ABC | abacavir |
| ACF | active TB case finding |
| AIDS | acquired immunodeficiency syndrome |
| ALT | alanine aminotransferase |
| ART | antiretroviral therapy |
| ARV | antiretroviral drugs |
| AST | aspartate aminotransferase |
| AZT | zidovudine |
| BCG | bacille Calmette-Guérin (vaccine) |
| CAD | computer aided detection |
| CFP-10 | culture filtrate protein 10 |
| CLHIV | children living with HIV |
| DDI | drug-drug interaction |
| DHIS2 | District Health Information Software 2 |
| DMPA | depot medroxyprogesterone acetate |
| DSD | differentiated HIV service delivery |
| ELISA | enzyme-linked immunosorbent assay |
| ESAT-6 | early secretory antigenic target-6 |

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_24750

